Presant CA - Search Results

1

Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits.

Wolf W, Presant CA, Servis KL, el-Tahtawy A, Albright MJ, Barker PB, Ring R 3rd, Atkinson D, Ong R, King M, et al. Wolf W, et al. Among authors: presant ca. Proc Natl Acad Sci U S A. 1990 Jan;87(1):492-6. doi: 10.1073/pnas.87.1.492. Proc Natl Acad Sci U S A. 1990. PMID: 2296605 Free PMC article.

2

Integrating Tobacco Treatment Into Oncology Care: Reach and Effectiveness of Evidence-Based Tobacco Treatment Across National Cancer Institute-Designated Cancer Centers.

Hohl SD, Matulewicz RS, Salloum RG, Ostroff JS, Baker TB, Schnoll R, Warren G, Bernstein SL, Minion M, Lenhoff K, Dahl N, Juon HS, Tsosie U, Fleisher L, D'Angelo H, Ramsey AT, Ashing KT, Rolland B, Nolan MB, Bird JE, Nguyen CVT, Pauk D, Adsit RT, Tindle HA, Shoenbill K, Yeung S, Presant CA, Wiseman KP, Wen KY, Chichester LA, Chen LS. Hohl SD, et al. Among authors: presant ca. J Clin Oncol. 2023 May 20;41(15):2756-2766. doi: 10.1200/JCO.22.00936. Epub 2022 Dec 6. J Clin Oncol. 2023. PMID: 36473135 Free PMC article.

3

Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.

Presant CA, Wolf W, Albright MJ, Servis KL, Ring R 3rd, Atkinson D, Ong RL, Wiseman C, King M, Blayney D, et al. Presant CA, et al. J Clin Oncol. 1990 Nov;8(11):1868-73. doi: 10.1200/JCO.1990.8.11.1868. J Clin Oncol. 1990. PMID: 2230874

4

Proposed criteria for serial evaluation of quality of life in cancer patients.

Presant CA, Wiseman C, Blayney D, Kennedy P, Gala K, King M. Presant CA, et al. J Natl Cancer Inst. 1990 Feb 21;82(4):322-3. doi: 10.1093/jnci/82.4.322. J Natl Cancer Inst. 1990. PMID: 2299682 No abstract available.

5

Association of intratumoral pharmacokinetics of fluorouracil with clinical response.

Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR. Presant CA, et al. Lancet. 1994 May 14;343(8907):1184-7. doi: 10.1016/s0140-6736(94)92399-x. Lancet. 1994. PMID: 7909867

6

5-Fluorouracil revisited: a new perspective for treatment planning.

Presant CA, Wolf W, Waluch V. Presant CA, et al. Ann Oncol. 1997 Feb;8(2):203-4. doi: 10.1093/oxfordjournals.annonc.a010861. Ann Oncol. 1997. PMID: 9093735 Free article. No abstract available.

7

Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies.

Wolf W, Waluch V, Presant CA. Wolf W, et al. Among authors: presant ca. NMR Biomed. 1998 Nov;11(7):380-7. doi: 10.1002/(sici)1099-1492(1998110)11:7<380::aid-nbm517>3.0.co;2-q. NMR Biomed. 1998. PMID: 9859944

8

Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy.

Presant CA, Wolf W, Waluch V, Wiseman CL, Weitz I, Shani J. Presant CA, et al. J Clin Oncol. 2000 Jan;18(2):255-61. doi: 10.1200/JCO.2000.18.2.255. J Clin Oncol. 2000. PMID: 10637237 Clinical Trial.

9

19F-MRS studies of fluorinated drugs in humans.

Wolf W, Presant CA, Waluch V. Wolf W, et al. Among authors: presant ca. Adv Drug Deliv Rev. 2000 Mar 15;41(1):55-74. doi: 10.1016/s0169-409x(99)00056-3. Adv Drug Deliv Rev. 2000. PMID: 10699305 Review.

10

Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study.

Presant CA, Jacobson J, Wolf W, Waluch V, Weitz IC, Macdonald JS; Southwest Oncology Group. Presant CA, et al. Invest New Drugs. 2002 Nov;20(4):369-76. doi: 10.1023/a:1020651311866. Invest New Drugs. 2002. PMID: 12448653 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters